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Syntheses of potent teixobactin analogues against methicillin-
resistant Staphylococcus aureus (MRSA) through the replacement 
of L-allo-enduracididine with its isosteres 
Anish Parmar, a Abhishek Iyer, a, b Daniel G. Lloyd,c Charlotte S. Vincent, c Stephen H. Prior, d 
Annemieke Madder, b Edward J. Taylor d and Ishwar Singh* a  
The recently discovered cyclic depsipeptide, teixobactin, is a highly potent antibiotic against multi-drug resistant pathogens 
such as methicillin-resistant Staphylococcus aureus (MRSA) and Mycobaterium tuberculosis. It comprises 4 D amino acids 
and a rare L-allo-enduracididine amino acid. The synthesis of a properly protected L-allo-enduracididine amino acid and its 
incorporation into teixobactin is time consuming, synthetically challenging and low yielding and is therefore a major 
bottleneck in the development of potent analogues of teixobactin. In this article, we have synthesised 8 analogues of 
teixobactin using commercially available building blocks by replacing the L-allo-enduracididine amino acid with its isosteres. 
Furthermore, we have tested all the compounds against a panel of Gram positive bacteria including MRSA and explained 
the observed trend in biological activity. Although all the analogues were active, three analogues from this work, showed 
very promising activity against MRSA (MIC 1 µg/mL). We can conclude that amino acids which are the closest isosteres of L-
allo-enduracididine are the key to synthesising simplified potent analogues of teixobactin using rapid syntheses and  
improved yields.
Antimicrobial resistance (AMR) is spreading faster than the 
introduction of new antibiotics resulting in a major health 
crisis.1 The recently discovered antibiotic teixobactin2 has 
shown tremendous promise due to its potent activity 
particularly against resistant pathogens such as Methicillin-
resistant Staphylococcus aureus (MRSA) and Mycobacterium 
tuberculosis. Teixobactin kills bacteria without detectable 
resistance2 through the inhibition of cell wall synthesis. It 
operates by inhibiting the non-protein building blocks,  lipid II 
(needed for peptidoglycan synthesis) and lipid III (a starting 
material for cell wall teichoic acid synthesis)  from multiple 
biosynthetic pathways, thereby making it difficult for bacteria 
to develop resistance against it.3 Therefore, teixobactin 
research has gained tremendous momentum with several 
research groups including our own showing a keen interest in 
designing and synthesising highly potent synthetic analogues of 
teixobactin. 
 
Teixobactin is an undecapeptide containing four D amino acids 
namely N-Me-D-Phe1, D-Gln4, D-allo-Ile5 and D-Thr8 and the rare 
L-allo-enduracididine amino acid (Figure 1A). In the past year, 
several notable contributions have been made to teixobactin 
research describing the total synthesis of teixobactin,4 5 and the 
syntheses and biological activities of teixobactin analogues.6 7 8 
We have established the importance of the D configuration of 
the amino acids of teixobactin in terms of antibacterial activity.9  
It was observed that changing the amino acid configuration of 
any one of the four D amino acids (D-N-Me-Phe1, D-Gln4, D-allo-
Ile5 and D-Thr8) from D to L leads to significant loss in 
antibacterial activity.9  We have further reported the three-
dimensional molecular structure of seven teixobactin analogues 
by using NMR. The NMR studies revealed that the disordered 
structure of teixobactin analogues is important for their 
biological activity. It was shown that D-Gln4 is essential and D-
allo-Ile5 is important for maintaining the disordered structure.9 
 
The minimum pharmacophore of teixobactin, lipobactin, has 
been reported by Nowick et. al.8 Lipobactin has been 
synthesised by replacing the N-terminal residues 1-5 with a 
dodecanoyl chain. Furthermore, Nowick et. al. also reported 
that modification of configuration of any of the residues in the 
core ring structure of teixobactin results in a significant 
decrease in activity. The enantiomeric Arg10-teixobactin which 
is a mirror image of Arg10-teixobactin shows similar biological 
activity as Arg10-teixobactin indicating that only the relative 
configurations of amino acids are important for maintaining 
biological activity and not their absolute configuration. Very 
recently, Nowick et. al. have reported the crystal structure of a 
truncated teixobactin analogue showing the key interactions of 
the core ring structure of teixobactin with a chloride ion.10 A  
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Figure 1: A. Teixobactin B. General structure of teixobactin analogues (1-8) with the hydrophilic/charged residues shown in red, hydrophobic residues shown in black and structural 
differences shown in blue.
lysine scan of Arg10-teixobactin reported by the Albericio 
group11 showed that replacement of any one of the four 
isoleucine residues with lysine leads to complete loss of activity. 
However, replacement of the polar, non-charged residues Ser3, 
Gln4 and non-polar Ala9 by lysine resulted in analogues which 
have comparable biological activity to that of Arg10-teixobactin. 
Recently, Wu. C et. al. reported that Lys10/Arg10, Ser7 and the 
NH- group of the N terminal phenylalanine are critical for the 
biological activity of teixobactin analogues.12 Replacement of 
Arg10 or Lys10 by His10, Ser7 by Ala7 and N-Methyl phenylalanine1 
by N, N-dimethyl phenylalanine1 leads to less active teixobactin 
analogues compared to Arg10-teixobactin. During the 
preparation of this manuscript, a series of teixobactin analogues 
using convergent Ser/Thr ligation was published by Li et. al. 
which reports the synthesis and antibacterial activity of 
NorArg10-teixobactin.13 
 
To further develop potent teixobactin analogues against 
resistant bacteria such as MRSA, we are particularly interested 
in understanding the role of the polar amino acid residues at 
position 10 namely L-allo-enduracididine, arginine and lysine. It 
has been suggested that L-allo-enduracididine is important for 
the biological activity of teixobactin.4 However, the synthesis of 
a properly protected L-allo-enduracididine and its subsequent 
incorporation in teixobactin synthesis is complex and low 
yielding (3.3% overall yield).4 Several research groups have 
substituted this amino acid with commercially available building 
blocks such as Arginine,6 7 Lysine8 or Histidine.12 The obtained 
analogues were less active than the natural product. However, 
the biological activity of teixobactin analogues suggests they are 
still suitable for further development as potential antibacterials. 
Therefore, it is important to synthesise new, potent derivatives 
with comparable biological activity to teixobactin which do not 
contain the L-allo-enduracididine amino acid. In this work, we 
have synthesised eight analogues of teixobactin using 
commercially available building blocks by replacing the L-allo-
enduracididine amino acid with a series of amino acids that can 
be considered isosters thereof. We have tested all the 
analogues (1-8) against a panel of Gram positive bacteria 
including MRSA to compare the biological activity with 
teixobactin. This study is aimed at deciphering the most suited 
amino acids which can replace L-allo-enduracididine. We 
believe that the amino acids which possess a similar structure 
and functional group (isostere) as the L-allo-enduracididine 
amino acid are best suited for its replacement.  The amino acids 
Lysine (Lys), Ornithine (Orn), L-2,4- Diaminobutyric acid (DAB) 
and L-1,3-Diaminopropionic acid (DAP) were chosen as these 
are the closest amine containing isosteres to L-allo-
enduracididine. Furthermore, through these amino acids we 
could sequentially shorten the side chain length by one 
methylene unit from 4 C atoms to 1 C atom. To further expand 
the number of teixobactin analogues and to reduce the overall 
cost and time taken by avoiding the re-syntheses of analogues 
containing non-natural guanidine side-chains, we have used a 
one-step route from our previous synthesis7 and inspired by the 
results of Tor et. al.14 to directly convert the deprotected amino-
side chains into their corresponding guanidines (Figure 2). For 
this purpose, the commercially available 1H-Pyrazole-
carboxamidine hydrochloride in MeOH with Et3N was used 
(Figure 2, page S3) followed by HPLC purification to remove any 
excess reagent present in the reaction mixture. By introducing 
Lys, Orn, DAB and DAP one at a time at position 10 we 
synthesised analogues Lys10-teixobactin (1), Orn10-teixobactin 
(3), Dab10-teixobactin (5) and Dap10-teixobactin (7) (figure 3). 
We then directly converted Lys10-teixobactin (1) to 
(Homoarginine) HoArg10-teixobactin (2), DAB10-teixobactin (5) 
to NorArg10-teixobactin (6) and DAP10-teixobactin (7) to (L-2-
amino-3-guanidinoaminopropionic acid) GAPA10-teixobactin (8) 
using the aforementioned protocols (Figure 2). We thus 
synthesised 8 teixobactin analogues namely Lys10-teixobactin 
(1), HoArg10-teixobactin (2), Orn10-teixobactin (3), Arg10-
teixobactin (4), DAB10-teixobactin (5), NorArg10-teixobactin (6), 
Figure 2: General scheme for the syntheses of teixobactin analogues 2, 6 and 8 from their amino precursors 1, 5 and 7 respectively. 
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Table 1: Minimum Inhibitory Concentration (MIC) values of compounds 1-10 against MRSA ATCC 33591, Staphylococcus epidermidis ATCC 12228 and Bacillus subtilis 
168.
DAP10-teixobactin (7) and GAPA10-teixobactin (8) (Figure 3). 
 
The syntheses and biological activity against Staphylococcus 
aureus of Lys10-teixobactin (1) 8 12, Orn10-teixobactin (3)5,  Arg10-
teixobactin (4) 6 7 and NorArg10-teixobactin13 have already been 
reported. There has been very limited evaluation of teixobactin 
analogues against MRSA. Among the synthesised analogues, 
Orn10-teixobactin (3) (MIC 2 µg/mL)5 and NorArg10-teixobactin13 
(MIC 16 µg/mL)13 are the only ones tested against MRSA. 
However, a different strain of MRSA was used. To address this, 
we have evaluated the antibacterial activity of our eight 
teixobactin analogues (1-8) against MRSA ATCC 33591 (identical 
to the strain reported in Nature2) to compare the biological 
activities with that of teixobactin (Table 1). All the analogues 
were also screened against Staphylococcus epidermidis and 
Bacillus subtilis to provide a more comprehensive overview of 
the biological activities of these molecules. Vancomycin was 
used as a control. 
 
Herein we report for the first time the MIC of Lys10-teixobactin 
(1) against MRSA which was found to be two times better than  
Figure 3: Complete structure of teixobactin analogues (1-8) and structure of L-allo-
enduracididine (B). The amino acids at position 10 and L-allo-enduracididine have 
been numbered and highlighted in red for clarity. 
Compound 
Number 
Name MIC against MRSA 
ATCC 33591 (µg/mL) 
MIC against Staphylococcus 
epidermidis ATCC 12228 (µg/mL) 
MIC against Bacillus 
subtilis 168 (µg/mL) 
1 Lys10-teixobactin 1 1 0.25 
2 HoArg10-teixobactin 1 0.25 0.125 
3 Orn10-teixobactin 2 1 0.25 
4 Arg10-teixobactin 2 2 1 
5 DAB10-teixobactin 2 2 1 
6 NorArg10-teixobactin 1 1 0.5 
7 DAP10-teixobactin 4 2 0.5 
8 GAPA10-teixobactin 4 4 1 
9 Teixobactin 0.252 0.078-0.312 0.022 
10 Vancomycin 2 2 0.25-0.5 
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that of Arg10-teixobactin (Table 1) against the same species. 
HoArg10-teixobactin (2) was found to have identical activity as 
Lys10- teixobactin. The MIC of Orn10-teixobactin5 (3) was found 
to be consistent with that reported in literature and identical to 
that of Arg10-teixobactin (4). The MIC of Dab10-teixobactin (5) 
was found to be identical to Orn10- teixobactin (3) (Table 1) 
which is expected as both DAB and Orn can be considered 
isosters of L-allo-Enduracididine (Figure 3). NorArg10 teixobactin 
(6) showed two times better MIC than Arg10-teixobactin (Table 
1) although both Norarginine and Arginine are isosteric with L-
allo- enduracididine. The difference can be potentially 
attributed to lower flexibility of 6 due to a reduced carbon chain 
length of NorArg and therefore being structurally more similar 
to L-allo-enduracididine. On further reducing the side-chain 
length of the amino acid at position 10 by one methylene group 
we obtained the analogues Dap10-teixobactin (7) and GAPA10-
teixobactin (8) which were found to be less active than 
analogues 1-6 in MRSA. Both Dap10-teixobactin (7) and GAPA10-
teixobactin (8) have an MIC two times higher than Arg10-
texiobactin (3). The higher MICs in MRSA are probably because 
although both DAP and GAPA have structural similarities to L-
allo-enduracididine (Figure 3), they have a shorter carbon chain 
thereby affording less flexibility. The MIC trend observed in 
Staphylococcus epidermidis and Bacillus subtilis is similar to that 
of MRSA. However, all compounds (1-8) have shown 2-4 times 
better MICs in B. subtilis compared to MRSA and S. epidermidis. 
HoArg10-teixobactin (2) was found to be the most potent 
analogue possessing the lowest MIC in all three species, 
followed by Lys10-teixobactin (1) and Orn10-teixobactin (3). 
Overall, the MICs observed are consistent with the hypothesis 
that the closest isosteres of L-allo-enduracididine are most 
suited for its replacement. 
 
In conclusion, we have synthesised 8 teixobactin analogues and 
tested them against a panel of Gram positive bacteria including 
MRSA to determine the most suited amino acids for replacing 
the synthetically challenging L-allo-enduracididine at position 
10. Furthermore, for the rapid syntheses of guanidine 
containing teixobactin analogues from amines, we have used 
the direct conversion of amines to guanidines for completely 
deprotected teixobactin analogues. This method is compatible 
with secondary amines as well as other amino acid side chains 
and will therefore be suitable for diverse peptides. Based on the 
MICs against MRSA, we observe that all the synthesised 
compounds are active and therefore can be used as leads for 
further derivatisation. Lysine, homoarginine and norarginine 
are all equally suitable substitutions for L-allo-enduracididine. 
Furthermore, almost no difference in MIC was observed 
between the amino derivatives and their corresponding 
guanidine counterparts. This implies that there is a considerable 
tolerance for the substitution of L-allo-enduracididine with both 
proteogenic and non-proteogenic amino acids containing amine 
or guanidine side-chains. We have synthesised eight potent 
teixobactin analogues three of which show very promising 
activity against MRSA (MIC 1 µg/mL). The results from this work 
are expected to facilitate the development of teixobactin 
analogues against MRSA and have the potential to address the 
challenges posed by multi-drug resistant bacteria. 
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